PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time
美国东部时间上午 8:30 的电话会议和网络直播
NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, May 14, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's first quarter 2024 financial results.
纽约，2024 年 5 月 3 日 /PRNewswire/-- PavMed Inc. 纳斯达克股票代码：PAVM、PAVMZ）（“PAVMed” 或 “公司”）是一家多元化的商业阶段医疗技术公司，在医疗器械、诊断和数字医疗领域开展业务。该公司今天宣布，它将在美国东部时间2024年5月14日星期二上午8点30分举办业务最新情况电话会议和网络直播。在电话会议上，PavMed董事长兼首席执行官Lishan Aklog医学博士将提供业务最新情况，包括公司的运营和增长战略概述。此外，PAVMed总裁兼首席财务官丹尼斯·麦格拉思将讨论公司2024年第一季度的财务业绩。
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
该网络直播将在公司网站pavmed.com的投资者关系部分播出。或者，要通过电话参加电话会议，美国的来电者应拨打1-800-836-8184，国际听众应拨打1-646-357-8785。所有听众都应向运营商提供电话会议名称 “PavMed 业务更新” 以加入。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
电话会议结束后，公司网站pavmed.com的投资者关系部分将提供为期30天的重播。
About PAVmed
关于 PAVMed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc., is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
PavMed Inc. 是一家多元化的商业阶段医疗技术公司，业务涉及医疗器械、诊断和数字医疗领域。其控股子公司Lucid Diagnostics Inc. 是一家商业阶段的癌症预防医疗诊断公司，负责销售ESOGuard 食管 DNA 测试和 ESOCheck 食管细胞收集设备——第一个也是唯一一个广泛早期发现食道癌前病变以降低食道癌死亡风险的商业工具。其另一家控股子公司Veris Health Inc. 是一家数字健康公司，专注于通过使用具有无线通信功能的植入式生物传感器以及定制的连接外部设备套件进行远程患者监测，从而增强个性化癌症护理。Veris正在同时开发一种可植入的生理监护仪，该监护仪可与化疗端口一起植入，它将与Veris癌症护理平台接口。
For more information about PAVmed, please visit pavmed.com.
有关 PavMed 的更多信息，请访问 pavmed.com。
For more information about Lucid Diagnostics, please visit luciddx.com.
有关 Lucid Diagnostics 的更多信息，请访问 luciddx.com。
For more information about Veris Health, please visit verishealth.com.
有关 Veris Health 的更多信息，请访问 verishealth.com。
SOURCE PAVmed Inc.
来源 PavMed Inc.